Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Kralik

Thoracic Surgery (Cardiothoracic Vascular Surgery) Phoenix, AZ Medical Doctor

NPI 1982642450 CMS profile 134768

1331 N 7Th Street, Suite 375, Phoenix, AZ 85006

Open in the dashboard

General payments

$9,421

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Kralik of Phoenix, AZ is reported in the CMS Open Payments database as having received $9,421 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,229 32
2024 General $2,874 14
2023 General $1,006 22
2022 General $1,274 12
2021 General $1,686 18
2020 General $115 5
2019 General $1,236 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Kralik
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Michael Kralik were reported at $1,229. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Michael Kralik Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $1,236 $886 $178–$3,167 $163
2020 $115 $341 $108–$1,605 $114
2021 $1,686 $453 $125–$1,886 $132
2022 $1,274 $695 $180–$2,566 $149
2023 $1,006 $745 $205–$2,662 $160
2024 $2,874 $799 $214–$2,967 $164
2025 $1,229 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $2,339 3 payments
  2. Edwards Lifesciences Corporation $2,274 20 payments
  3. Endologix, Inc. $1,611 31 payments
  4. Medtronic, Inc. $1,510 21 payments
  5. Atricure, Inc. $713 8 payments
  6. Boston Scientific Corporation $142 7 payments
  7. Abiomed $126 2 payments
  8. NuVasive, Inc. $125 3 payments
  9. W. L. Gore & Associates, Inc. $95 5 payments
  10. Chiesi USA, Inc. $81 2 payments
  11. Other $407 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,672 106 payments
  2. Travel and Lodging $3,471 16 payments
  3. Long term medical supply or device loan $2,278 1 payment
  4. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $2,278 1 payment
  2. VENASEAL $1,472 18 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,139 6 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $1,031 12 payments
  5. AFX2 Bifurcated Endograft System $908 20 payments
  6. SYNERGY ABLATION SYSTEM $713 8 payments
  7. Alto Abdominal Stent Graft System $703 11 payments
  8. AtriCure cryoICE cryoSPHERE Cryoablation System $529 5 payments
  9. Impella $126 2 payments
  10. ALIF $125 3 payments
  11. Other $999 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

100

Median for Thoracic Surgery: 42

Drug cost

$30,601

Median for Thoracic Surgery: $318

Branded share of claims

100%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 24 $15,571
Eliquis Apixaban Brand 25 $14,534
Clopidogrel Clopidogrel Bisulfate Brand 51 $495

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$4,964

Medicare's payments for the services billed

Medicare patients

13

Average age 75

Services billed

16

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record